IGLV2 8 | ENSG00000278196 | NCBI 28817

Details for: IGLV2 8

Gene ID: 28817

Gene Type: Other - A known gene or region type that lacks a specific category. Includes immunoglobulin (Ig), T-cell receptor (TCR) gene segments, and repetitive elements.

Symbol: IGLV2 8

Ensembl ID: ENSG00000278196

Description: immunoglobulin lambda variable 2-8

Cell Significance Landscape

Display Count:

Associated with

Adaptive immune system
(R-HSA-1280218)
Anti-inflammatory response favouring leishmania parasite infection
(R-HSA-9662851)
Antigen activates b cell receptor (bcr) leading to generation of second messengers
(R-HSA-983695)
Binding and uptake of ligands by scavenger receptors
(R-HSA-2173782)
Cd22 mediated bcr regulation
(R-HSA-5690714)
Cell surface interactions at the vascular wall
(R-HSA-202733)
Classical antibody-mediated complement activation
(R-HSA-173623)
Complement cascade
(R-HSA-166658)
Creation of c4 and c2 activators
(R-HSA-166786)
Disease
(R-HSA-1643685)
Fc epsilon receptor (fceri) signaling
(R-HSA-2454202)
Fceri mediated ca+2 mobilization
(R-HSA-2871809)
Fceri mediated mapk activation
(R-HSA-2871796)
Fceri mediated nf-kb activation
(R-HSA-2871837)
Fcgamma receptor (fcgr) dependent phagocytosis
(R-HSA-2029480)
Fcgr3a-mediated il10 synthesis
(R-HSA-9664323)
Fcgr3a-mediated phagocytosis
(R-HSA-9664422)
Fcgr activation
(R-HSA-2029481)
Hemostasis
(R-HSA-109582)
Immune system
(R-HSA-168256)
Immunoregulatory interactions between a lymphoid and a non-lymphoid cell
(R-HSA-198933)
Infectious disease
(R-HSA-5663205)
Initial triggering of complement
(R-HSA-166663)
Innate immune system
(R-HSA-168249)
Leishmania infection
(R-HSA-9658195)
Leishmania parasite growth and survival
(R-HSA-9664433)
Leishmania phagocytosis
(R-HSA-9664417)
Parasite infection
(R-HSA-9664407)
Parasitic infection pathways
(R-HSA-9824443)
Potential therapeutics for sars
(R-HSA-9679191)
Regulation of actin dynamics for phagocytic cup formation
(R-HSA-2029482)
Regulation of complement cascade
(R-HSA-977606)
Role of lat2/ntal/lab on calcium mobilization
(R-HSA-2730905)
Role of phospholipids in phagocytosis
(R-HSA-2029485)
Sars-cov infections
(R-HSA-9679506)
Scavenging of heme from plasma
(R-HSA-2168880)
Signaling by the b cell receptor (bcr)
(R-HSA-983705)
Vesicle-mediated transport
(R-HSA-5653656)
Viral infection pathways
(R-HSA-9824446)
Adaptive immune response
(GO:0002250)
Antigen binding
(GO:0003823)
Extracellular region
(GO:0005576)
Immune response
(GO:0006955)
Immunoglobulin complex
(GO:0019814)
Plasma membrane
(GO:0005886)

Significant Cells

Cell Significance Index (CSI) scores for the chosen context(s)

plasmablast CL0000980

CSI 3.6

rCSI 2.83%

PRS 99.04
IgA plasma cell CL0000987

CSI 3.5

rCSI 3.58%

PRS 98.28
IgG plasma cell CL0000985

CSI 3

rCSI 3.59%

PRS 98.99

Cell ID: Standard Cell Ontology term used for mapping and comparing cells across experiments. Ensures consistency in analyzing cellular functions across tissues.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.

Network Configuration

Explore relationships of the current gene. Select an Interaction Source: 'ONTOLOGY' for shared pathways (GO/Reactome) or 'STRING' for protein-protein interactions. Further refine by selecting context genes and comparing Cell Significance Index (CSI) scores between baseline and target cell types and their specific contexts.

Context Genes (max 20):

Interaction Source:

Pathway Categories (for ONTOLOGY source):

Baseline Cell Type:

Baseline Cell Context(s): Comma-separated if multiple.

Target Cell Type:

Target Cell Context(s): Comma-separated if multiple.

Legend:

Query Gene
Node Color (Target Cell CSI, relative to current network):
- Very High
- High
- Medium
- Low
- Very Low
- CSI N/A
Node Size: Proportional to Target Cell CSI magnitude
STRING PPI Edge
Shared Pathway Edge (ONTOLOGY)

Loading network (please wait)...

Other Information

This section provides additional information about the gene, including a description generated by an AI language model and details about associated proteins.

Description

## Summary [IGLV2 8](/details-gene/28817) is a gene segment encoding the variable (V) region of an immunoglobulin lambda light chain. As a fundamental component of the adaptive immune system, it contributes to the vast diversity of antibodies required for antigen recognition. Its primary function is to form part of the antigen-binding site of B-cell receptors and secreted antibodies. **Overall**, expression data indicates that [IGLV2 8](/details-gene/28817) is a highly significant and specific marker for terminally differentiated, antibody-secreting cells, particularly `[plasmablasts](/details-cell/CL0000980)` and both `[IgA](/details-cell/CL0000987)` and `[IgG](/details-cell/CL0000985)` `[plasma cells](/details-cell/CL0000987)`. ## Cellular Roles and Expression Landscape The expression profile of [IGLV2 8](/details-gene/28817) points to a highly specialized role in the humoral immune response. Its significance is overwhelmingly concentrated in the B-cell lineage, specifically in cells actively engaged in antibody production. * **Primary Expression Context:** The gene shows the highest significance in `[plasmablasts](/details-cell/CL0000980)` (CSI: 3.60), which are immediate precursors to plasma cells. * **Terminal B-Cell Lineage:** High significance is also observed in mature, isotype-switched `[IgA plasma cells](/details-cell/CL0000987)` (CSI: 3.50) and `[IgG plasma cells](/details-cell/CL0000985)` (CSI: 3.00). This expression pattern is consistent with its function as a V-gene segment, which is transcribed at high levels following B-cell activation and differentiation into antibody-secreting effector cells. The data strongly suggests that [IGLV2 8](/details-gene/28817) is a key contributor to the antibody repertoire produced by these cell populations. ## Pathways and Molecular Function The functional annotations for [IGLV2 8](/details-gene/28817) are tightly linked to its role in immunity. According to Gene Ontology, its molecular function is centered on `[antigen binding](/details-go/GO:0003823)`, a process essential for the `[adaptive immune response](/details-go/GO:0002250)`. It is a component of the `[immunoglobulin complex](/details-go/GO:0019814)` located on the `[plasma membrane](/details-go/GO:0005886)` of B-cells or in the `[extracellular region](/details-go/GO:0005576)` as a secreted antibody. Reactome pathway analysis further reinforces this role, placing [IGLV2 8](/details-gene/28817) within the broader framework of the `[adaptive immune system](/details-pathway/R-HSA-1280218)`. Its involvement is critical for upstream events such as `[antigen activates b cell receptor (bcr) leading to generation of second messengers](/details-pathway/R-HSA-983695)` and downstream effector functions mediated by the resulting antibodies. These include `[classical antibody-mediated complement activation](/details-pathway/R-HSA-173623)` and `[Fcgamma receptor (fcgr) dependent phagocytosis](/details-pathway/R-HSA-2029480)`. The extensive involvement in pathways related to `[infectious disease](/details-pathway/R-HSA-5663205)`, including `[leishmania infection](/details-pathway/R-HSA-9658195)` and `[viral infection pathways](/details-pathway/R-HSA-9824446)`, highlights the functional importance of antibodies incorporating this specific V-gene segment in host defense. ## Research Directions The specific usage and functional implications of an individual V-gene segment like [IGLV2 8](/details-gene/28817) are critical areas of immunology research, with potential relevance to infection, autoimmunity, and cancer. ### Proposed Hypotheses 1. **Pathogen-Specific Repertoire Skewing:** The [IGLV2 8](/details-gene/28817) segment may be preferentially selected and expanded in B-cell responses against specific classes of antigens (e.g., viral glycoproteins or bacterial polysaccharides), making it a dominant component of the protective antibody response in certain infections. 2. **Role in Autoimmunity and Malignancy:** Clonal B-cell populations in diseases like multiple myeloma or certain autoimmune disorders (e.g., systemic lupus erythematosus) might exhibit biased usage of [IGLV2 8](/details-gene/28817) to produce pathogenic autoantibodies or form the malignant B-cell receptor. Somatic hypermutations within this gene segment could be critical for driving disease pathology. ### Experimental Approach To test the hypothesis regarding its role in malignancy, a powerful approach would be to perform single-cell RNA sequencing coupled with V(D)J repertoire analysis (sc-V(D)J-seq) on bone marrow aspirates from patients with multiple myeloma. This would enable researchers to precisely quantify the usage frequency of [IGLV2 8](/details-gene/28817) within the malignant `[plasma cell](/details-cell/CL0000987)` population compared to residual healthy `[plasma cells](/details-cell/CL0000987)` from the same patient or from healthy donors. Furthermore, analyzing the patterns of somatic hypermutation within the expressed [IGLV2 8](/details-gene/28817) segment could reveal selection pressures and identify recurrent mutations associated with the cancerous clone. ### Therapeutic Potential As a gene segment, [IGLV2 8](/details-gene/28817) itself is not a direct drug target. However, the unique antigen-binding surface (idiotype) created by an antibody that incorporates [IGLV2 8](/details-gene/28817) can be a highly specific therapeutic target. If a malignant B-cell clone or a population of autoantibody-producing cells preferentially uses [IGLV2 8](/details-gene/28817), it could be targeted for inhibition or depletion. This could be achieved through therapies such as anti-idiotype antibodies or CAR-T cells engineered to recognize the specific B-cell receptor, offering a highly personalized treatment strategy that spares healthy immune cells.

Disclaimer: This in-silico analysis is generated by an AI language model and may contain inaccuracies or hallucinations. However, it is cross-referenced with curated gene expression data from major biological sources. Please verify the information before use.